Halozyme Therapeutics, Inc. (HALO)
Piper Jaffray 2013 Healthcare Conference
December 3, 2013 12:00 PM ET
Gregory Frost - President, CEO and Director
Charles Duncan - Piper Jaffray
Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc.
(NASDAQ:HALO) announced today that Baxter has completed submission of an
amended biologics license application (BLA) to the United States Food
Halozyme Therapeutics is expected to book a narrower loss than a year ago when it reports third quarter earnings on Friday, November 8, 2013 with analysts expecting a loss of 16 cents per share, up from a loss of 18 cents per share a year ago.
Nektar Therapeutics (Nasdaq: NKTR) 26.4% LOWER; announced the preliminary topline results from a Phase 2 study of NKTR-181 for the treatment of moderate-to-severe chronic pain in patients with osteoarthritis of the knee. The Phase 2 study utilized...
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the commercial launch of Herceptin® SC in Europe has triggered a $10 million milestone payment to Halozyme under the License and Collaboration Agreement between Halozyme and Roche....
Google's Maps and Earth products are a good way to pass some idle time, zooming around the globe, but they're also tools that can be put to use in scenarios with considerable social impact. The search giant has detailed its partnership with...
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.